Barden
Chris Barden, Halifax CA
Patent application number | Description | Published |
---|---|---|
20100076028 | Design and Synthesis of Novel Antimicrobials - The synthesis and activity of novel LpxA inhibitors is described, these inhibitors present antibacterial activity. The compounds were designed based on a receptor model developed using the crystal structure of LpxA and are arranged to have a favorable binding interaction at the active site of the enzyme. In particular, the compounds present the following formula (I) where V, W, X, Y and Z can be independently C, S, N or O and P1, P2 and P3 are ligands to bind to the three points of the proposed pharmacophore model. They can be chosen from a variety of groups. | 03-25-2010 |
Christopher J. Barden, Lake Side CA
Patent application number | Description | Published |
---|---|---|
20140187556 | ANTI-AMYLOID COMPOUNDS AND METHODS - Anti-amyloid compounds are provided along with methods of use thereof. | 07-03-2014 |
Christopher J. Barden, Lakeside CA
Patent application number | Description | Published |
---|---|---|
20110218200 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE - The present invention is directed to compounds that inhibit amyloid aggregation and methods of treatment there-with. | 09-08-2011 |
Christopher J. Barden, Halifax CA
Patent application number | Description | Published |
---|---|---|
20100137388 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof - The present invention provides for therapies characterized in part by co-administration or combination of antibiotic agents with medicinal compositions comprising as the pro-antibiotic active ingredient either a compound represented by a formula [I] or a pharmaceutically acceptable composite thereof; [wherein X represents oxygen, sulfur, NH, or N-alkyl; R | 06-03-2010 |
20140309266 | ANTIMICROBIAL/ADJUVANT COMPOUNDS AND METHODS - Among other things, in general, antimicrobial and/or adjuvant compounds are provided according to Formula Ia: (Ia) in which E and R1-11 have the meanings described herein; and prodrugs and pharmaceutically acceptable salts thereof. Other formulae and methods of use are also provided. | 10-16-2014 |
Christopher J. Barden, Toronto CA
Patent application number | Description | Published |
---|---|---|
20150266838 | BENZOFURAZAN ANTI-AMYLOID COMPOUNDS AND METHODS - In general, among other things, compounds of Formula I are provided: | 09-24-2015 |
Julian Barden, Marsfield AU
Patent application number | Description | Published |
---|---|---|
20080227122 | P2Y PURINERGIC RECEPTOR EXPRESSION FOR IDENTIFYING PRENEOPLASTIC AND NEOPLASTIC STATES - The present invention relates to methods for identifying pre-neoplastic and neoplastic states in mammals and in particular to a method for identifying pre-neoplasia and neoplasia in cells and tissues based on differential expression of P2Y purineric receptors. | 09-18-2008 |
20110111431 | METHOD FOR IDENTIFYING PRE-NEOPLASTIC AND/OR NEOPLASTIC STATES IN MAMMALS - The present invention relates to methods of identifying pre-neoplastic and/or neoplastic states in mammals and in particular to a method for identifying pre-neoplastic and neoplastic cells in tissues and body fluids, based on differential expression of purinergic receptors in these cells. | 05-12-2011 |
Julian Alexander Barden, Marsfield AU
Patent application number | Description | Published |
---|---|---|
20090192293 | ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR - The present invention provides antibodies that specifically bind to P2X | 07-30-2009 |
20110092674 | Non-Functional P2X7 Receptor - The present invention provides antibodies that specifically bind to P2X | 04-21-2011 |
20120059151 | Non-Functional P2X7 Receptor - The present invention provides antibodies that specifically bind to P2X | 03-08-2012 |
20130245226 | Antibodies To Non-Functional P2X7 Receptor - The present invention provides antibodies that specifically bind to P2X | 09-19-2013 |
20140323693 | Antibodies To Non-Functional P2X7 Receptor - The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between functional and non-functional p2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions. | 10-30-2014 |
Julian Alexander Barden, New South Wales AU
Patent application number | Description | Published |
---|---|---|
20100105068 | HYBRIDOMAS PRODUCING ANTIBODIES AGAINST NON FUNCTIONAL P2X7 RECEPTOR - The present invention relates to the production of anti non functional P2X7 receptor monoclonal antibodies from hybridoma cell lines. | 04-29-2010 |
20100248266 | PURINERGIC (P2X) RECEPTORS IN EXTRA-CELLULAR BODY FLUID - The invention relates to purinergic (P2X) receptors, to detection of protein in extra-cellular body fluids and to antibodies for the diagnosis of a disease or condition, especially cancer. | 09-30-2010 |
20110177080 | NOVEL P2X7 EPITOPES - The invention relates to purinergic (P2X) receptors, more specifically to P2X7 receptors, the generation of antibodies and the use of antibodies and immunogens that are capable of selectively binding to a non ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor, for the detection and treatment of disease conditions, especially cancer. | 07-21-2011 |
Julian Alexander Barden, North Ryde AU
Patent application number | Description | Published |
---|---|---|
20100036101 | ANTIBODIES AGAINST NON FUNCTIONAL P2X7 RECEPTOR - A recombinant or synthetic antibody or fragment thereof, said antibody or fragment thereof including three complementarity determining regions (CDR1 | 02-11-2010 |
20110110959 | ANTI-P2X7 PEPTIDES AND EPITOPES - The invention relates to the identification of a novel epitope on non-functional P2X | 05-12-2011 |
20120282278 | ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF - The invention relates to an antigen binding site for binding to a P2X | 11-08-2012 |
20120329076 | Antibodies to Non-Functional Oligomeric P2X7 Receptors - The invention relates to purinergic receptors, to antibodies and related fragments thereof for binding to said receptors, to production of said antibodies and fragments and to use of said antibodies and fragments for cancer detection and therapy. In particular the antibodies described bind specifically to non-functional P2X7 receptors expressed by live cells. | 12-27-2012 |
20130171666 | Purinergic (P2X) Receptors in Extra-Cellular Body Fluid - The invention relates to purinergic (P2X) receptors, to detection of protein in extra-cellular body fluids and to anti-bodies for the diagnosis or condition, especially cancer. | 07-04-2013 |
20130266592 | COMPANION ANIMAL TREATMENTS - The invention relates to minimising the progression of cancer in a companion animal using P2X7 immunotherapy. | 10-10-2013 |
20130273085 | Novel P2X7 Epitopes - The invention relates to purinergic (P2X) receptors, more specifically to P2X7 receptors, the generation of antibodies and the use of antibodies and immunogens that are capable of selectively binding to a non ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor, for the detection and treatment of disease conditions, especially cancer. | 10-17-2013 |
20140135475 | ANTIBODIES FOR BINDING TO NON-FUNCTIONAL P2X7 RECEPTORS IN TRIMERIC FORM - The invention relates to a novel epitope on P2X7 receptors, to antibodies for binding to the epitope and to peptides for generating the antibodies. | 05-15-2014 |
20150218283 | Antibodies to Non-Functional Oligomeric P2X7 Receptors - The invention relates to purinergic receptors, to antibodies and related fragments thereof for binding to said receptors, to production of said antibodies and fragments and to sue of said antibodies and fragments for cancer detection and therapy. In particular the antibodies described bind specifically to non-functional P2X& receptors expressed by live cells. | 08-06-2015 |
20150266969 | ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF - The invention relates to an antigen binding site for binding to a P2X | 09-24-2015 |
20150274839 | Antibodies to Non-Functional P2X7 Receptor - The present invention provides antibodies that specifically bind to P2X | 10-01-2015 |
Michaael C. Barden, Auchenflower AU
Patent application number | Description | Published |
---|---|---|
20120214973 | USE OF METAL COMPLEXES - A method of immobilising a target molecule on a substrate, which comprises exposing the target molecule to the substrate in the presence of a metal complex, wherein the target molecule is an unmodified target molecule, and wherein the metal complex is selected to provide a stable binding interaction between the target molecule and the substrate. | 08-23-2012 |
Michael C. Barden, Queensland AU
Patent application number | Description | Published |
---|---|---|
20090209049 | USE OF METAL COMPLEXES - A method of immobilising a target molecule on a substrate, which comprises exposing the target molecule to the substrate in the presence of a metal complex, wherein the target molecule is an unmodified target molecule, and wherein the metal complex is selected to provide a stable binding interaction between the target molecule and the substrate. | 08-20-2009 |
Michael C. Barden, Auchenflower AU
Patent application number | Description | Published |
---|---|---|
20160103126 | USE OF METAL COMPLEXES - A method of immobilising a target molecule on a substrate, which comprises exposing the target molecule to the substrate in the presence of a metal complex, wherein the target molecule is an unmodified target molecule, and wherein the metal complex is selected to provide a stable binding interaction between the target molecule and the substrate. | 04-14-2016 |
Nicholas Barden, Sainte-Foy CA
Patent application number | Description | Published |
---|---|---|
20080200411 | MEANS AND METHODS FOR DIAGNOSING AND TREATING AFFECTIVE DISORDERS - Nucleic acid molecules encoding an ATP-gated ion channel P2X7R which contains a mutation or a deletion are disclosed. Polypeptides encoded by the nucleic acid molecules and antibodies that specifically are directed to these polypeptides are disclosed. Aptamers that specifically bind the nucleic acid molecules, and primers for selectively amplifying the nucleic acid molecules are provided, kits, compositions, particularly pharmaceutical and diagnostic compositions comprising the nucleic acid molecules, vectors, polypeptides, aptamers, antibodies and/or primers, are provided. Methods for diagnosing affective disorders associated with a non-functional P2X7R protein, an altered ATP-gating of the P2X7R protein, an over or underexpression of the P2X7R protein or associated with the presence of any one of the nucleic acid molecules or polypeptides encoded thereby are disclosed. Additionally, the present invention relates to uses and methods for treating affective disorders employing a functional or non-functional ATP-gated ion-channel P2X7R, such as treatment with modulators of P2X7R activity. | 08-21-2008 |
Richard Mark Barden, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20090141649 | Communication System and Method - In a communications system a transmitter is arranged to transmit asynchronous transfer mode (ATM) cells in which synchronous transfer mode (STM) channels are assembled. In order to minimise the bandwidth required at lease some of the ATM cells include one or more switch command(s) ( | 06-04-2009 |
20160057003 | NODE PARTITIONING - A set of wireless nodes is provided, in which a subset of the wireless nodes are also wired nodes. A method of processing the set comprises performing a node initialisation, thereby linking nodes in the set of wireless nodes, performing a link evaluation, thereby determining a quality characteristic of links between nodes, and segmenting the nodes into partitions, each partition comprising at least one wired node and each node in a partition having a link to another node in the same partition with the determined quality characteristic above a predetermined threshold. | 02-25-2016 |